Obstacles in combating multidrug resistant tuberculosis in pediatric patients: a scope review / Obstáculos no combate à tuberculose multidroga resistente em pacientes pediátricos: uma revisão de escopo

Abstract Objectives: to identify the scientific evidence on excessively resistant and multidrug resistant tuberculosis in pediatric patients. Methods: this is a scope review of the literature, with a guiding question: "What is the scientific evidence on multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis in pediatric patients?". The research used the descriptors: "extensively drug-resistant tuberculosis" OR "multidrug-resistant tuberculosis" AND "pediatrics". The research was carried out in a double-blind manner in the following databases of the Medical Literature Analysis and Retrieval System Online, Regional Office for the Western Pacific's Institutional Repository for Information Sharing, Embase/Elsevier and International Clinical Trials Registry Platform, with a temporal cut-off from 2011 to 2021, sending a final synthesized sample of 18 articles, which evaluated the methodological content through the level of evidence. Results: the results show the lack of research with a high level of evidence related to MDR-TB in children, the lack of adequate dosage of second-line drugs for the pediatric population and the importance of drug sensitivity testing for the cases of treatment Conclusions: it was identified that the obstacles to MDR-TB treatment were concentrated in the lack of detailed protocols, safe drug dosages with a low side effect, and mainly in the social health determinants and disease process involving MDR-TB.

Resumo Objetivos: identificar as evidências científicas sobre tuberculose excessivamente resistente e multidroga resistente em pacientes pediátricos. Métodos: trata-se de uma revisão de escopo da literatura, tendo como questão norteadora: "Quais as evidências científicas sobre tuberculose multidroga-resistente (TB-MDR) e tuberculose extensivamente resistente em pacientes pediátricos?" A pesquisa usou os descritores: "tuberculose extensivamente resistente a medicamentos" OR "tuberculose resistente a múltiplos medicamentos" AND "pediatria". A pesquisa foi realizada de modo duplo-cego nas bases de dados Medical Literature Analysis and Retrieval System Online, Regional Office for the Western Pacific's Institutional Repository for Information Sharing, Embase/Elsevier e International Clinical Trials Registry Platform, com um corte temporal de 2011 a 2021, sendo a amostra final sintetizada de 18 artigos, nos quais avaliou-se o conteúdo metodológico por meio do nível de evidência. Resultados: os resultados mostraram a escassez de pesquisas de alto nível de evidência relacionadas à TB-MDR em crianças, ausência de posologia adequada das drogas de segunda linha para o público pediátrico e a importância do teste de sensibilidade a drogas para o tratamento dos casos. Conclusões: identificou-se que os obstáculos do tratamento TB-MDR se concentraram na ausência de protocolos detalhados, de dosagens medicamentosas seguras e com menor efeito colateral, e, principalmente, nos determinantes sociais do processo saúde e doença que envolvem a TB-MDR.

Clinical and epidemiological features of tuberculosis isolated from critically ill patients / Tuberculosis en la unidad de cuidados intensivos: características clínicas y epidemiológicas

Human tuberculosis is still a major world health concern. In Uruguay, contrary to the world trend, an increase in cases has been observed since 2006. Although the incidence of MDR-resistant strains is low and no cases of XDR-TB were registered, an increase in the number of patients with severe tuberculosis requiring critical care admission was observed. As a first aim, we performed the analysis of the genetic structure of strains isolated from patients with severe tuberculosis admitted to an intensive care unit. We compared these results with those corresponding to the general population observing a statistically significant increase in the Haarlem genotypes among ICU patients (53.3% vs 34.7%; p;<;0.05). In addition, we investigated the association of clinical outcomes with the genotype observing a major incidence of hepatic dysfunctions among patients infected with the Haarlem strain (p;<;0.05). The cohort presented is one of the largest studied series of critically ill patients with tuberculosis.

La tuberculosis (TB) aún representa un problema mayor de salud pública. En Uruguay, contrariamente a la tendencia mundial, se ha observado un incremento en el número de casos desde 2006. Aunque la incidencia de casos de multidrogorresistencia (MDR) es baja y no se han reportados casos de resistencia a fármacos de primera y segunda línea de tratamiento (XDR), se ha observado un incremento en el número de casos con TB grave, que requieren internación en unidad de terapia intensiva (CTI). Como primer objetivo del presente trabajo, se analizó la estructura genética de cepas de Mycobacterium tuberculosis aisladas de pacientes internados en CTI. Comparamos estos resultados con los obtenidos con cepas circulantes en la comunidad. Observamos un incremento estadísticamente significativo del genotipo Haarlem en los pacientes internados en CTI (53,3 vs. 34,7%; p;<;0,05). Además, investigamos la asociación del desenlace clínico con el genotipo, y encontramos una mayor incidencia de disfunción hepática en los pacientes infectados con la cepa Haarlem (p;<;0,05). La cohorte presentada en este trabajo corresponde a una de las series con mayor número de pacientes con tuberculosis que requirieron internación en CTI.

Impacto da implantação do teste rápido molecular para a tuberculose no Brasil / Impact of roll out of rapid molecular test for tuberculosis in Brazil

Introdução: A tuberculose (TB) ainda se apresenta como um grave problema de saúde pública no mundo, com mais de 10 milhões de casos e 1,3 milhão de mortes anualmente. Em 2020, no Brasil, foram notificados 66.819 casos novos de TB, e aproximadamente 913 casos de TB drogarresistente. Cerca de 4.500 pessoas vão a óbito, anualmente, por TB no país. Com as tecnologias atuais, a melhor estratégia para controlar a transmissão e reduzir a incidência da TB é o diagnóstico e tratamento dos casos pulmonares bacilíferos, associados ao diagnóstico e tratamento da infecção latente. O Brasil incorporou, em 2014, o teste rápido molecular (TRM), recomendando-o como estratégia inicial para diagnóstico da TB e detecção da resistência à rifampicina (TB-RR). A presente tese buscou descrever e analisar o impacto da implantação do teste rápido molecular para tuberculose sobre os indicadores programáticos para o controle da tuberculose no Brasil, e o efeito do teste rápido molecular no início do tratamento em casos de tuberculose resistentes à rifampicina e/ou multidrogarresistente. Métodos: foram realizados estudos observacionais, com dados secundários. O primeiro, trata-se de um estudo ecológico cujas unidades de análise foram os municípios que compõe a rede de teste rápido molecular para TB (RTR-TB), e foram analisados os indicadores da TB antes e depois do início de utilização do TRM. Foi utilizada a modelagem de séries temporais interrompidas pela Regressão de Prais-Winsten. O segundo estudo teve como desenho uma coorte retrospectiva, tomando o indivíduo como unidade de análise. Foi utilizado o método de análise de sobrevida para avaliar o efeito do TRM sobre o tempo entre o diagnóstico e o início do tratamento dos casos novos de TB-RR / TB-MDR. A Regressão de Cox foi utilizada para estimação dos riscos proporcionais. Resultados: no período estudado, a RTR-TB consumiu um total de 1.756.358 cartuchos de TRM, sendo 1.734.935 testes realizados. A notificação de casos novos de TB na série histórica trimestral de janeiro de 2010 a junho de 2014 apresentou tendência estacionária. Após a implantação do TRM-TB, verificou-se uma tendência de aumento médio da ordem de 0,5% (IC 95%: 0,13 - 0,87) de casos novos, por trimestre, e em todo o período pós-intervenção, houve um incremento de 8.241 casos novos de TB nos municípios da RTR-TB, um aumento de 15% (IC 95%: 10,71 - 19,46) no nível de confirmação laboratorial dos casos novos de TB, e uma queda de 8,42% (IC 95%: -15,61 - -0,62) na realização de baciloscopia. Entre 2014 e 2019, 2.071 casos de TB-RR / TB-MDR tiveram o diagnóstico da resistência por meio do TRM, e 1.592 por meio do TSA. Após a incorporação do TRM, houve uma redução no tempo médio de início do tratamento da resistência em 89 dias (p-valor < 0,0001), quando comparado ao TSA. Indivíduos diagnosticados pelo TRM apresentam maior probabilidade de iniciar o tratamento da TB-DR mais precocemente quando comparado aos indivíduos diagnosticados pelo TSA, e essa diferença é mais acentuada até os primeiros 60 dias após o diagnóstico. Indivíduos diagnosticados pelo TSA apresentaram probabilidade 78% menor de iniciar o tratamento nos primeiros 30 dias após o diagnóstico da resistência quanto comparado aos indivíduos diagnosticados pelo TRM (HRadj: 0,22; IC95%: 0,13 - 0,36), e 49% menor probabilidade de iniciar o tratamento nos primeiros seis meses após o diagnóstico quando comparado aos indivíduos diagnosticados pelo TRM (HRadj: 0,51; IC95%: 0,39 - 0,62). Conclusões: o TRM apresentou, de forma global, impacto positivo nas estratégias de controle da TB do Brasil, reestruturando a rede de diagnóstico da doença, aumentando a confirmação laboratorial, e diminuindo o tempo entre o diagnóstico e o início do tratamento da TB-RR / TB-MDR. A incorporação do TRM no SUS propiciou um diagnóstico da doença mais rápido e com maior sensibilidade, viabilizando um diagnóstico muito mais oportuno da TB-RR / TB-MDR, e encurtando o tempo para início do tratamento da TB resistente. A ampliação do diagnóstico rápido molecular por TRM para os municípios que ainda não compõe a RTR-TB podem contribuir para um melhor controle da TB no país.

Introduction: Tuberculosis (TB) still is as a serious public health problem in the world, with more than 10 million cases and 1.3 million deaths annually. In 2020, in Brazil, 66.819 new cases of TB and approximately 913 cases of drug-resistant TB were notified. About 4,500 persons die annually from TB in the country. With the current technologies available, the best strategies to control the transmission and to reduce the TB incidence is the diagnosis and treatment of the bacilliferous pulmonary cases, associated with the diagnosis and treatment of latent infection. In 2014, Brazil has incorporated the rapid molecular test (TRM), recommending it as an initial strategy for diagnosing TB and detecting rifampicin resistance (TB-RR). The present thesis describes and analyses the impact of the roll out of the TRM for TB on the programmatic indicators for TB control in Brazil, and the effect of the TRM in the beginning of the treatment in cases of tuberculosis resistant to rifampicin and/or multidrugresistent. Methods: observational studies were performed with routine data. The first study was an ecological study whose units of analysis were the municipalities that make up the rapid molecular testing network for TB (RTR-TB), and TB indicators were analyzed before and after the beginning of TRM use. The modeling of time series interrupted by the Prais-Winsten Regression was used. The second study was a retrospective cohort, whose the individual was the unit of analysis. The survival analysis method was used to assess the effect of TRM on the time between diagnosis and initiation of treatment of new cases of RR-TB / MDR-TB. Cox regression was used to estimate proportional hazards. Results: in the period studied, the RTR-TB consumed a total of 1,756,358 TRM cartridges, with 1,734,935 tests performed. The notification of new TB cases in the quarterly historical series from January 2010 to June 2014 showed a stationary trend. After the implementation of the TRM-TB, there was a trend towards an average increase of around 0.5% (95% CI: 0.13 - 0.87) of new cases, per quarter-year, and throughout the post-intervention period, there was an increase of 8,241 new TB cases in the municipalities of RTR-TB, a 15% increase (95% CI: 10.71 - 19.46) in the level of laboratory confirmation of new TB cases, and a decrease of 8.42% (95% CI: -15.61 - -0.62) in performing smear microscopy. Between 2014 and 2019, 2,071 RR-TB/MDR-TB cases were diagnosed with resistance through TRM, and 1,592 through TSA. After the incorporation of TRM, there was a reduction in the mean time of initiation of resistance treatment by 89 days (p-value < 0.0001), when compared to TSA. Individuals diagnosed by TRM are more likely to start DR-TB treatment earlier when compared to individuals diagnosed by TSA, and this difference is more accentuated up to the first 60 days after diagnosis. Persons diagnosed by TSA were 78% less likely to start the treatment in the first 30 days after the diagnosis of resistance when compared to those diagnosed by TRM (HRadj: 0.22; 95% CI: 0.13 - 0.36), and 49% lower probability of starting the treatment in the first six months after the diagnosis when compared to those diagnosed by TRM (HRadj: 0.51; 95%CI: 0.39 - 0.62). Conclusions: Overall, the TRM had a positive impact on TB control strategies in Brazil, restructuring the disease diagnosis network, increasing laboratory confirmation, and reducing the time between diagnosis and initiation of TB-RR / TB-MDR treatment. The incorporation of TRM into the Public Health System in Brazil provided a faster and more sensitive diagnosis of the disease, enabling a much more timely diagnosis of RR-TB / MDR-TB, and shortening the time to start treatment for resistant TB. The expansion of rapid molecular diagnosis by TRM to municipalities that are not yet part of the RTR-TB may contribute to better control of the disease in the country.

Tuberculose multirresistente: análise epidemiológica em um hospital de ensino / Multidrug-resistant tuberculosis: epidemiological analysis at a teaching hospital / Tuberculosis multiresistente: análisis epidemiológico en un hospital docente

Objetivo: Descrever o perfil epidemiológico dos pacientes diagnosticados com Tuberculose Multirresistente em um hospital de ensino de referência na cidade do Rio de Janeiro. Método: Estudo descritivo, quantitativo, desenvolvido em uma instituição terciária de ensino de referência para tratamento de TBMR na cidade do Rio de Janeiro. Foi utilizado instrumento estruturado com informações de quarenta prontuários. A análise dos dados foi realizada através do software SPSS. Resultados: A média de idade encontrada nos 40 pacientes diagnosticados com TBMR foi de 43.6 anos, 40% tinham menos de 7 anos de estudo e 70% se declararam pardos ou negros. Conclusão: Foi verificada uma alta prevalência de pacientes na faixa etária de 21-40 anos, bem como uma alta proporção de pacientes com baixa escolaridade

Objective:The study's goal has been to describe the epidemiological profile of patients diagnosed with Multidrug-resistant tuberculosis (MDR-TB) at a referral teaching hospital in the Rio de Janeiro city. Methods: It is a descriptive and cross-sectional study with a quantitative approach, which was carried out at a referral tertiary teaching hospital for the treatment of MDR-TB in the Rio de Janeiro city. A structured instrument was used with information from 40 medical records. Data analysis was performed using the SPSS software. Results: The average age found for 40 patients diagnosed with MDR-TB was 43.6 years old, 40% had less than 7 (seven) years of education and 70% were either self-declared brown or black. Conclusion: There was verified a high prevalence of patients within the age group from 21 to 40 years old, as well as a high number of patients having low education

Objetivo: Describir el perfil epidemiológico de los pacientes diagnosticados con Tuberculosis Multirresistente en un hospital de enseñanza de referencia en la ciudad de Río de Janeiro. Método: Estudio descriptivo, cuantitativo, desarrollado en una institución terciaria de enseñanza de referencia para tratamiento de TBMR en la ciudad de Río de Janeiro. Se utilizó un instrumento estructurado con información de cuarenta registros. El análisis de los datos se realizó a través del software SPSS. Resultados: La media de edad encontrada en los 40 pacientes diagnosticados con TBMR fue de 43.6 años, 40% tenían menos de 7 años de estudio y el 70% se declaró pardos o negros. Conclusión: Se verificó una alta prevalencia de pacientes en el grupo de edad de 21-40 años, así como una alta proporción de pacientes con baja escolaridad

Early detection of Pre-XDR TB with line probe assay in a high TB burden country

Background - Worldwide, tuberculosis (TB) is one of the top 10 causes of death. Drug resistant tuberculosis has lately become a major public health problem that threatens progress made in Tuberculosis (TB) care and control worldwide. The aim of this study was to determine the prevalence of Pre-extensive drug resistant TB among MDR TB in North Central of Nigeria. Methods - This study was conducted from October, 2018 to August, 2019 with 150 samples. In Nigeria, guidelines for DR-TB as recommended by WHO is followed. All the samples from the patients who gave their consent were transported to a zonal reference TB laboratory (ZRL). Results - Mean age was 38.6 ± 13.4 years with peak age at 35-44. Out of these 103 samples processed with LPA, 101(98%) were rifampicin resistant and 2 were rifampicin sensitive, 99(96%) were INH resistant and 4 (4%) were INH sensitive, 5(5%) were fluoroquinolone resistant, 98(95%) were fluoroquinolone sensitive, 12 (12%) were Aminoglycoside + Capreomycin resistant, 91(83%) were Aminoglycoside + Capreomycin sensitive. Conclusion - Multidrug resistant TB and its severe forms (Pre-extensive & extensively drug resistant TB) can be detected early with rapid tool- Line Probe Assay rapid and prevented timely by early initiation on treatment.

Adverse treatment outcomes in multidrug resistant tuberculosis go beyond the microbe-drug interaction: Results of a multiple correspondence analysis / Los resultados adversos en el tratamiento de la tuberculosis resistente a múltiples fármacos sobrepasan la relación fármaco-microorganismo: resultados de un análisis de correspondencia múltiple

Abstract . Introduction: Multidrug-resistant tuberculosis treatment is effective in 50% of patients due to several factors including antibiotic susceptibility of the microorganism, adverse treatment reactions, social factors, and associated comorbidities. Objectives: In this study, we describe the demographics, clinical characteristics, and factors associated with treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) patients in Medellín, Colombia. Materials and methods: We conducted a retrospective analysis using data from patients diagnosed with MDR-TB attending Hospital La María in Medellín, Colombia, for treatment between 2010 and 2015. Patients were categorized as having successful (cured) or poor (failure, lost to follow-up, and death) treatment outcomes. Associations between demographic, clinical factors, laboratory results, treatment outcomes, and follow-up information were evaluated by univariate, multivariate, and multiple correspondence analyses. Results: Of the 128 patients with MDR-TB, 77 (60%) had successful outcomes. Of those with poor outcomes, 26 were lost to follow-up, 15 died, and 10 were treatment failures. Irregular treatment, the presence of comorbidities, and positive cultures after more than two months of treatment were associated with poor outcomes compared to successful ones (p<0.05 for all). The multiple correspondence analyses grouped patients who were lost to follow-up, had HIV, and drug addiction, as well as patients with treatment failure, irregular treatment, and chronic obstructive pulmonary disease. Conclusion: The recognition of factors affecting treatment is essential and was associated with treatment outcomes in this series of patients. Early identification of these factors should increase the rates of treatment success and contribute to MDR-TB control.

Resumen . Introducción. El tratamiento de la tuberculosis multirresistente tiene una efectividad del 50 %, afectado por múltiples factores como la sensibilidad del microorganismo, las reacciones secundarias, los factores sociales y las comorbilidades existentes. Objetivos. Describir la demografía, las características clínicas y los factores pronósticos asociados con los resultados del tratamiento en pacientes multirresistentes (TB-MDR) de Medellín, Colombia. Métodos. Se hizo un análisis retrospectivo de los datos de los pacientes con TB-MDR atendidos en el Hospital La María de Medellín, Colombia, que fueron tratados entre el 2010 y el 2015. Los pacientes se categorizaron con tratamiento exitoso (curados) o con tratamiento fallido (falla en el tratamiento, pérdida durante el seguimiento y muerte). Se determinó la asociación entre las características demográficas y clínicas, los resultados de los exámenes de laboratorio, los desenlaces del tratamiento y la información del seguimiento, utilizando análisis univariado, multivariado y de correspondencia múltiple. Resultados. De 128 pacientes con TB-MDR, 77 (60 %) tuvieron un tratamiento exitoso. De los que tuvieron un tratamiento fallido, 26 pacientes se perdieron en el seguimiento, 15 murieron y 10 tuvieron falla en el tratamiento. El tratamiento irregular, las comorbilidades y los cultivos positivos más allá de 2 meses de tratamiento se asociaron significativamente con los tratamientos fallidos (p<0,05). El análisis de correspondencia múltiple agrupó los pacientes con pérdida en el seguimiento, con HIV y tratamientos irregulares, y los pacientes con tratamientos irregulares y enfermedad pulmonar obstructiva crónica con falla en el tratamiento y muerte. Conclusión. El reconocimiento temprano de los factores que afectan el desenlace del tratamiento de los pacientes con TB-MDR es esencial; la identificación de dichos factores debería incrementar el éxito del tratamiento y contribuir al adecuado control de la TB-MDR.

Evaluation of the QuantaMatrix Multiplexed Assay Platform for Molecular Diagnosis of Multidrug- and Extensively Drug-Resistant Tuberculosis Using Clinical Strains Isolated in Myanmar

BACKGROUND: Although the incidence of tuberculosis (TB) is decreasing, cases of multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB continue to increase. As conventional phenotype drug susceptibility testing (pDST) takes six to eight weeks, molecular assays are widely used to determine drug resistance. we developed QuantaMatrix Multiplexed Assay Platform (QMAP) MDR/XDR assay (QuantaMatrix Inc., Seoul, Korea) that can simultaneously detect mutations related to both first- and second-line drug resistance (rifampin, isoniazid, ethambutol, fluoroquinolones, second-line injectable drugs, and streptomycin). METHODS: We used 190 clinical Mycobacterium tuberculosis (MTB) strains isolated from Myanmar, compared QMAP and pDST results, and determined concordance rates. Additionally, we performed sequence analyses for discordant results. RESULTS: QMAP results were 87.9% (167/190) concordant with pDST results. In the 23 isolates with discordant results, the QMAP and DNA sequencing results completely matched. CONCLUSIONS: The QMAP MDR/XDR assay can detect all known DNA mutations associated with drug resistance for both MDR- and XDR-MTB strains. It can be used for molecular diagnosis of MDR- and XDR-TB to rapidly initiate appropriate anti-TB drug therapy.

Frequency of first and second-line drug resistance-associated mutations among resistant Mycobacterium tuberculosis clinical isolates from São Paulo, Brazil

BACKGROUND Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis, and the number of new cases of multidrug resistant TB (MDR-TB), pre extensively drug-resistant TB (pre-XDR-TB) and extensively drug-resistant TB (XDR-TB) has increased considerably worldwide. OBJECTIVES Herein, using 156 M. tuberculosis isolates from 106 patients previously classified as MDR or pre-XDR or XDR isolates, we investigated the genetic mutation profiles associated with phenotypic resistances in patients with MDR-TB, pre-XDR-TB and XDR-TB, treatment outcomes and resistance evolution. METHODS Molecular analyses were performed by partial sequencing of the rpoB, katG, gyrA, gyrB, rrs genes and analysis of the fabG-inhA promoter region. Clinical, epidemiologic and demographic data were obtained from the TB Notification database system of São Paulo (TB-WEB) and the Information System for Special Tuberculosis Treatments (SITE-TB). FINDINGS Drug resistance was attributed to previously known mutations and a novel Asp449Val mutation in gyrB was observed in four isolates from the same patient. Ten patients had more than one isolate evaluated and eight of these patients displayed resistance progression. MAIN CONCLUSIONS The present study is the first to report the frequency of mutations related to second-line drug resistance in MDR-TB, pre-XDR-TB and XDR-TB isolates. The results could lead to the improvement of available technologies for the rapid detection of drug resistant TB.

Serie de casos: tuberculosis extremadamente resistente a drogas en Colombia, 2006-2016 / Extensively resistant tuberculosis, Colombia, 2006-2016

Introducción. La tuberculosis extremadamente resistente a los medicamentos (TB-XDR) es el resultado de deficiencias en la administración del tratamiento y en la prevención de la transmisión de la enfermedad; además, es un reto para los programas nacionales de control de la tuberculosis. Objetivo. Describir las características clínicas y epidemiológicas de los casos de TB-XDR diagnosticados en Colombia. Materiales y métodos. Se trata de un estudio de serie de casos, de pacientes con diagnóstico de TB-XDR, de 2006 a 2016 en Colombia. Las fuentes de información fueron el formato único de vigilancia y la base de datos del Laboratorio Nacional de Referencia. Se analizaron las variables: entidad territorial de procedencia, sexo, edad, régimen de afiliación, forma de tuberculosis, coinfección tuberculosis-HIV, patrón de sensibilidad a los fármacos de segunda línea y resultado (vivo o muerto). Resultados. En el período de estudio, se diagnosticaron 51 casos de TB-XDR, 28 hombres y 23 mujeres, con un promedio anual de cinco casos. En los departamentos de Antioquia, Valle del Cauca y Atlántico, se presentaron 46 (90 %) de los casos. El rango de edad fue de 5 a 81 años y, la mediana, de 40 años. De los 51 pacientes, 32 (63 %) estaban afiliados al régimen subsidiado de salud y 46 (90 %) presentaron tuberculosis pulmonar; de los 22 a quienes se les practicó la prueba para HIV, en tres (13,6 %) había coinfección con HIV, y 29 (57 %) murieron. Los fármacos a los cuales hubo mayor resistencia, fueron ofloxacina en 45 (88 %) casos y amikacina en 43 (84 %). Conclusión. La TB-XDR se presentó principalmente en formas pulmonares, lo cual aumenta la probabilidad de transmisión en la comunidad y se refleja en la aparición de tuberculosis resistente en menores de 15 años. La población más afectada es la económicamente activa, con una gran mortalidad. El Programa Nacional de Prevención y Control de la Tuberculosis debe generar estrategias para evitar la propagación de cepas resistentes.

Introduction: Extensively drug-resistant tuberculosis (XDR-TB) is a result of deficiencies in the administration of treatment and transmission of the disease, being a challenge for national programs of tuberculosis control. Objective: To describe the clinical and epidemiological characteristics of the cases diagnosed in Colombia. Materials and methods: Case series study, performed on people diagnosed with XDRTB during 2006 to 2016 in Colombia. Information source: unique surveillance format and database of the national reference laboratory. The variables territorial entity of origin, gender, age, affiliation regime, form of tuberculosis, tuberculosis-HIV coinfection, sensitivity pattern to second line drugs and live/dead outcome were analyzed. Results: In this period, 51 XDR-TB cases have been diagnosed, with an annual average of five cases. Antioquia, Valle del Cauca and Atlántico present 90% (46) of cases. Age range: 5 to 81 years, median: 40 years. There were 28 men (55%) of the cases. Subsidized affiliation regime: 63% (32/51). Pulmonary form: 90% (46/51). TB-HIV coinfection: 13.6% (3/22). The drugs with greater resistance: ofloxacin 90% (45/51) and amikacin 86% (43/51). Dead unlink: 57% (29/51). Conclusion: XDR-TB occurred mainly in pulmonary forms increasing the probability of transmission in the community, which is reflected in the appearance of resistance in children under 15 years of age. The most affected population is economically active, with high mortality. The national program of tuberculosis control must generate strategies to avoid the spread of resistance that is affecting children and the economically active population, with high mortality.

Predictors of time to sputum culture conversion in multi-drug-resistant tuberculosis and extensively drug-resistant tuberculosis in patients at Tshepong-Klerksdorp Hospital

Setting: Klerksdorp-Tshepong Hospital Complex MDR-TB Unit, North-West Province, South Africa.Background: To determine the time to sputum culture conversion (TTSCC) and factors predictive of TTSCC in patients with multi-drug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) in the North-West Province.Methods: A retrospective cohort study, abstracting patient demographic and clinical data, laboratory results, dates of sputum testing and sputum culture conversion results, from medical records of 526 MDR-TB and 47 XDR-TB patients started on TB treatment between 01 January 2012 and 31 December 2014. Predictors of TTSCC were determined by Cox proportional hazards regression.Results: The median age was 38 years (interquartile range 31­47) with 64% being male. Overall, 79% (449) were Human Immunodeficiency Virus (HIV)-infected. The median TTSCC was 56.5 days and 162.5 days for MDR-TB and XDR-TB patients, respectively. In the multivariate analysis, age [hazard ratio (HR): 0.89, 95% confidence interval (CI): 0.96­0.99], being underweight (HR: 0.631.61, 95% CI: 0.451.03­0.882.51), Acid Fast Bacilli (AFB) positivity (HR: 0.72, 95% CI: 0.51­1.01) and having XDR-TB (HR: 0.36. 95% CI: 0.19­0.69) were predictive of longer TTSCC.Conclusion: Predictors of TTSC allow for MDR-TB- and XDR-TB-diagnosed patients to be identified early for effective management. Those with risk factors for delayed sputum culture conversion which are being underweight and having XDR-TB should be monitored carefully during treatment so that they can achieve sputum culture conversion early

Tuberculosis congénita pre-extensivamente resistente a drogas: reporte de caso / Pre-extensively drug-resistant congenital tuberculosis: case report

RESUMEN La tuberculosis en el lactante es un cuadro de difícil diagnóstico por las pruebas diagnósticas que muchas veces resultan negativas y por la dificultad de identificar la fuente de transmisión. Se presenta el caso de un lactante varón de un mes de vida que presenta irritabilidad, taquipnea, fiebre, pobre ganancia de peso desde el nacimiento y hepatomegalia, además, tiene el antecedente materno de tuberculosis pre-extensivamente resistente a drogas y reacción granulomatosa tuberculoide con tinción auramina positiva para bacilos ácido-alcohol resistentes en la histopatología de placenta. Ante la sospecha de tuberculosis congénita, es referido al Instituto Nacional de Salud del Niño para estudio diagnóstico y tratamiento; el paciente presenta una evolución clínica favorable y sin reacciones adversas al tratamiento. El diagnóstico de tuberculosis congénita debe considerarse en lactantes con signos clínicos sugestivos de la enfermedad y mantener la sospecha ante la presencia del antecedente materno de infección por Mycobacterium tuberculosis.

ABSTRACT Tuberculosis in infants is a clinical case difficult to diagnose by regular testing which often yield negative results; additionally, the source of transmission is difficult to identify. This work presents the case of a one-month old nursing boy presenting irritability, tachypnea, fever, poor gain weight from birth, and hepatomegaly. Additionally, he had the maternal history of pre-extensively drug- resistant tuberculosis and tuberculoid granulomatosis reaction with positive auramine tincture for acid-alcohol resistant bacilli at histopathology of the placenta. With a suspected congenital tuberculosis, he was referred to the National Children's Health Institute for diagnosis and treatment. The patient showed a favorable clinical evolution and no adverse reactions to treatment. The diagnosis of congenital tuberculosis must be considered in infants with suggestive clinical signs of the disease and such suspicion must be maintained with the presence of a maternal history of Mycobacterium tuberculosis infection.

New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis / Novos fármacos e fármacos repropostos para o tratamento da tuberculose multirresistente e extensivamente resistente

ABSTRACT Multidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB, respectively) continue to represent a challenge for clinicians and public health authorities. Unfortunately, although there have been encouraging reports of higher success rates, the overall rate of favorable outcomes of M/XDR-TB treatment is only 54%, or much lower when the spectrum of drug resistance is beyond that of XDR-TB. Treating M/XDR-TB continues to be a difficult task, because of the high incidence of adverse events, the long duration of treatment, the high cost of the regimens used, and the drain on health care resources. Various trials and studies have recently been undertaken (some already published and others ongoing), all aimed at improving outcomes of M/XDR-TB treatment by changing the overall approach, shortening treatment duration, and developing a universal regimen. The objective of this review was to summarize what has been achieved to date, as far as new and repurposed drugs are concerned, with a special focus on delamanid, bedaquiline, pretomanid, clofazimine, carbapenems, and linezolid. After more than 40 years of neglect, greater attention has recently been paid to the need for new drugs to fight the "white plague", and promising results are being reported.

RESUMO A tuberculose multirresistente (TB-MDR, do inglês multidrug-resistant) e a extensivamente resistente (TB-XDR, do inglês extensively drug-resistant) continuam representando um desafio para os clínicos e as autoridades de saúde pública. Infelizmente, embora haja relatos encorajadores de taxas de sucesso maiores, a taxa global de desfechos favoráveis do tratamento da TB-MDR/XDR é de apenas 54%, ou muito menor quando o espectro de resistência aos fármacos vai além do da TB-XDR. O tratamento da TB-MDR/XDR continua sendo uma tarefa difícil, em razão da alta incidência de eventos adversos, do longo tempo de tratamento, do alto culto dos esquemas utilizados e da drenagem dos recursos de saúde. Diversos ensaios e estudos foram realizados recentemente (alguns já publicados e outros em andamento), todos visando a melhorar os desfechos do tratamento da TB-MDR/XDR por meio da alteração da abordagem geral, redução do tempo de tratamento e desenvolvimento de um esquema universal. O objetivo desta revisão foi resumir o que se conseguiu até o momento, no que se refere a novos fármacos e fármacos repropostos, dando foco especial para delamanid, bedaquilina, pretomanida, clofazimina, carbapenêmicos e linezolida. Após mais de 40 anos de negligência, recentemente foi dada mais atenção á necessidade de novos fármacos para se combater a "praga branca", e resultados promissores estão sendo relatados.

Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea

BACKGROUND: Delamanid, bedaquiline, and linezolid have recently been approved for the treatment of multidrug- and extensively drug-resistant (MDR and XDR, respectively) tuberculosis (TB). To use these drugs effectively, drug susceptibility tests, including rapid molecular techniques, are required for accurate diagnosis and treatment. Furthermore, mutation analyses are needed to assess the potential for resistance. We evaluated the minimum inhibitory concentrations (MICs) of these three anti-TB drugs for Korean MDR and XDR clinical strains and mutations in genes related to resistance to these drugs. METHODS: MICs were determined for delamanid, bedaquiline, and linezolid using a microdilution method. The PCR products of drug resistance-related genes from 420 clinical Mycobacterium tuberculosis strains were sequenced and aligned to those of M. tuberculosis H37Rv. RESULTS: The overall MICs for delamanid, bedaquiline, and linezolid ranged from ≤0.025 to >1.6 mg/L, ≤0.0312 to >4 mg/L, and ≤0.125 to 1 mg/L, respectively. Numerous mutations were found in drug-susceptible and -resistant strains. We did not detect specific mutations associated with resistance to bedaquiline and linezolid. However, the Gly81Ser and Gly81Asp mutations were associated with resistance to delamanid. CONCLUSIONS: We determined the MICs of three anti-TB drugs for Korean MDR and XDR strains and identified various mutations in resistance-related genes. Further studies are needed to determine the genetic mechanisms underlying resistance to these drugs.

A Retrospective Study of Culture-confirmed Mycobacterial Infection among Hospitalized HIV-infected Patients in Beijing, China / 生物医学与环境科学（英文）

A retrospective analysis was performed in two major HIV/AIDS referral hospitals in Beijing to evaluate the prevalence of Mycobacterium tuberculosis (MTB) and non-tuberculous mycobacterial (NTM) infections in HIV-infected patients. A total of 627 patients' data were reviewed, and 102 (16.3%) patients were diagnosed with culture-confirmed mycobacterial infection, including 84 with MTB, 16 with NTM, and 2 with both MTB and NTM. The most frequent clinical complication by mycobacterial infection was pulmonary infection (48/102, 47.1%). The overall rates of multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) were 11.9% and 3.4%, respectively. This study underlines the urgent need to intensify screening for mycobacteria coinfection with HIV and to prevent the spread of drug-resistant TB among HIV-infected patients.

Frequência e perfil epidemiológico de pacientes com tuberculose multirresistente e extensivamente resistente em um hospital de referência na cidade do Rio de Janeiro / Frequency and epidemiological profile of patients with multidrug-resistant and extensively drug-resistant tuberculosis in a reference hospital in the city of Rio de Janeiro

A Tuberculose Multirresistente (TBMR) é um dos grandes problemas de saúde enfrentados em países em desenvolvimento, apresentando-se como um grande desafio global para o controle da Tuberculose (TB). Destacamos ainda o surgimento de formas mais graves de resistência, como a Tuberculose Extensivamente Resistente (TB-XDR). No Brasil foram implantadas diversas estratégias e ações com o objetivo de garantir o controle da doença, sua erradicação e redução nos indices de abandono terapêutico. Porém, na cidade do Rio de Janeiro, o índice de incidência da doença permanece elevado e se destaca como um dos mais altos do Brasil. O presente estudo tem por objetivos, avaliar a frequência e o perfil epidemiológico de pacientes com TBMR e TB-XDR diagnosticados em um Hospital de referência no município do Rio de Janeiro, no período de 2016 a 2018, com a determinação de contribuir para a geração de dados epidemiológicos sobre a situação da doença na cidade do Rio de Janeiro, identificar o grupo de pessoas mais vulneráveis, ajudar a completar o quadro clínico da doença além de estimular outros estudos, sobre o conhecimento da TBMR e TB-XDR. Estudo foi descritivo transversal. Os dados foram secundários coletados através de informações disponíveis em prontuários de pacientes diagnosticados com TB que tiveram como desfecho de interesse a resistência às medicações. Para a obtenção dos dados foi utilizado um instrumento estruturado, que possibilitou a captura de informações referentes à frequencia, o perfil sociodemográfico, características clínico-epidemiológicas, dentre outros. Foi realizada análise das variáveis sociodemógraficas, epidemiológicas e história de tratamento anterior com os resultados coletados armazenados em um banco de dados específico, sendo as análises de frequências e de associações realizadas por meio do software estatístico SPSS. Foram coletados dados de 100 pacientes com TBMR, 44% deles abandonaram o tratamento anteriormente. Dos pacientes investigados 61.6% eram do sexo masculino e 38.4% do sexo feminino. A média de idade encontrada neste estudo foi de 37.9 anos, com a variação entre 18 e 77 anos, 45.3% se declararam pardos e 39.3% possuíam de 4-7 anos de estudo, 19% dos pacientes apresentaram coinfecção HIV/TBMR, foi verificada associação entre abandono de tratamento anterior e caso de TBMR. Podemos concluir que os pacientes que foram encaminhados para tratamento no hospital de estudo apresentaram uma taxa elevada de casos de abandono de tratamento de tuberculose, o que se faz necessário o incremento de ações de planejamento para a adesão ao tratamento da tuberculose.

Multidrug-resistant tuberculosis (MDR-TB) is one of the major health problems faced in developed and developing countries, presenting itself as a major global challenge for Tuberculosis (TB) control. We also highlight the emergence of more severe forms of resistance, such as Extensively Resistant Tuberculosis (TB-XDR). In Brazil several strategies and actions were implemented with the objective of guaranteeing the control of the disease, its eradication and reduction in the rates of therapeutic abandonment. However, in the city of Rio de Janeiro, the incidence rate of the disease remains high and stands out as the highest in Brazil. The present study aims to evaluate the prevalence and epidemiological profile of patients with MDR-TB and MDR-TB diagnosed in a reference hospital in the city of Rio de Janeiro, from 2016 to 2018, with the determination to contribute to the generation epidemiological data on the disease situation in the city of Rio de Janeiro, identifying the group of most vulnerable individuals, helping to complete the clinical picture of the disease, and stimulating other studies on the knowledge of MDR-TB and XDR-TB. The thesis is that patients with MDR-TB and XDR-TB reported in a referral hospital in the city of Rio de Janeiro had abandoned previous treatment. Descriptive cross-sectional study. The data were collected through information available in medical records of patients diagnosed with TB who had as an outcome of interest the resistance to medications. To obtain the data, a structured instrument was used, which enabled the capture of information regarding prevalence, sociodemographic profile, clinical and epidemiological characteristics, among others. An analysis of sociodemographic, epidemiological and previous treatment history was performed with the collected data stored in a specific database, and the frequency and association analyzes were performed using the SPSS statistical software. Data were collected from 100 patients with MDR-TB, 44% of whom had previously discontinued treatment. Of the patients investigated, 61.6% were male and 38.4% female. The mean age found in this study was 37.9 years, ranging from 18 to 77 years, 45.3% were declared pardos and 39.3% had 4-7 years of schooling, 19% of the patients had HIV / MDR coinfection, was verified association between early cessation of treatment and case of MDR-TB. We can conclude that the study hospital had a high rate of cases of abandonment of tuberculosis treatment, which necessitates an increase in planning actions for adherence to tuberculosis treatment.

La Tuberculosis Multirresistente (TBMR) es uno de los grandes problemas de salud enfrentados en los países desarrollados y en desarrollo, presentándose como un gran desafío global para el control de la Tuberculosis (TB). Estamos de acuerdo con el surgimiento de formas más graves de resistencia, la Tuberculosis Extensivamente Resistente (TB-XDR). En Brasil se implantaron diversas estrategias y acciones con el objetivo de garantizar el control de la enfermedad, su erradicación y reducción en las tasas de abandono terapéutico. Sin embargo, en la ciudad de Río de Janeiro, el índice de incidencia de la enfermedad permanece elevado y se destaca como el más alto de Brasil. El presente estudio tiene por objetivos, evaluar la prevalencia y el perfil epidemiológico de pacientes con TBMR y TB-XDR diagnosticados en un Hospital de referencia en el municipio de Río de Janeiro, en el período de 2016 a 2018, con la determinación de contribuir a la generación de datos epidemiológicos sobre la situación de la enfermedad en la ciudad de Río de Janeiro, identificar el grupo de personas más vulnerables, ayudar a completar el cuadro clínico de la enfermedad además de estimular otros estudios, sobre el conocimiento de la TBMR y TB-XDR. la tesis es que los pacientes de TBMR y TB-XDR notificados en un hospital de referencia en la ciudad de Río de Janeiro tuvieron abandono de tratamiento anterior. Estudio descriptivo transversal. Los datos fueron recolectados a través de informaciones disponibles en prontuarios de pacientes diagnosticados con TB que tuvieron como resultado de interés la resistencia a las medicaciones. Para la obtención de los datos se utilizó un instrumento estructurado, que posibilitó la captura de informaciones referentes a la prevalencia, el perfil sociodemográfico, características clínico-epidemiológicas, entre otros. Se realizaron análisis de las variables sociodemóficas, epidemiológicas e historia de tratamiento anterior con los resultados recogidos almacenados en un banco de datos específico, siendo los análisis de frecuencias y de asociaciones realizadas por medio del software estadístico SPSS. Se recogieron datos de 100 pacientes con TBMR, el 44% de ellos abandonaron el tratamiento anteriormente. De los pacientes investigados 61.6% eran del sexo masculino y 38.4% del sexo femenino. La media de edad encontrada en este estudio fue de 37.9 años, con la variación entre 18 y 77 años, el 45.3% se declaró pardos y el 39.3% poseía de 4-7 años de estudio, el 19% de los pacientes presentaron coinfección VIH / TBMR, fue verificada asociación entre el abandono del tratamiento anterior y el caso de TBMR. Podemos concluir que el hospital de estudio presentó una tasa elevada de casos de abandono de tratamiento de tuberculosis, lo que se hace necesario el incremento de acciones de planificación para la adhesión al tratamiento de la tuberculosis.

Precisión diagnóstica de tres pruebas moleculares para detectar la tuberculosis multirresistente / Diagnostic accuracy of three technologies for the diagnosis of multi-drug resistant tuberculosis

Resumen Introducción. La tuberculosis multirresistente (TB-MDR) y la extremadamente resistente (TB-XDR) constituyen un problema de salud pública a nivel mundial. Su detección oportuna permitiría reducir la carga de la enfermedad y su impacto económico en los sistemas de salud. Objetivo. Revisar sistemáticamente la información relacionada con la precisión diagnóstica de tres pruebas moleculares para detectar la tuberculosis multirresistente y la extremadamente resistente. Materiales y métodos. Se hizo una revisión sistemática de la literatura, según los lineamientos de Cochrane, de los estudios en población inmunocompetente relacionados con la precisión diagnóstica de tres pruebas moleculares para detectar la tuberculosis multirresistente y la extremadamente resistente. La búsqueda de los estudios publicados a partir del 2007 se hizo en Medline y Embase. La precisión diagnóstica de las pruebas se estableció con base en los valores máximos y mínimos de sensibilidad y especificidad, y en los valores predictivos positivos y negativos. Resultados. Se detectaron ocho estudios sobre la precisión diagnóstica de la prueba GeneXpert MTB/RIF(r), 12 sobre la de GenoType MTBDRplus(r) y 13 sobre la de GenoType MTBDRsl(r). La especificidad de GeneXpert MTB/RIF(r) osciló entre 91 y 100 % y su sensibilidad, entre 33,3 y 100 %. La sensibilidad de GenoType MTBDRplus(r) varió entre 82 y 100 %, en tanto que la sensibilidad y la especificidad de GenoType(r) MTBDRsl fluctuaron entre 56 y 100 % y 21 y 100 %, respectivamente. Conclusión. Según los estudios consultados, los tres métodos de diagnóstico evaluados presentabanuna adecuada eficacia diagnóstica para detectar la tuberculosis multirresistente y la extremadamente resistente.

Abstract Introduction: Multi-drug resistant (MDR-TB) and extensively drug-resistant (XDR-TB) tuberculoses are a global public health problem. Their timely detection might reduce the burden of the disease and the economic impact on health systems worldwide. Objective: To conduct a literature review of the diagnostic accuracy of three molecular tests to detect multi-drug resistant and extensively drug-resistant tuberculoses. Materials and methods: A systematic literature review following Cochrane methodology was carried out to study the diagnostic accuracy of three molecular tests to detect MDR-TB and XDR-TB in previous studies among immunocompetent population. Articles indexed in Medline and Embase were reviewed starting in 2007. Diagnostic accuracy was reported by sensitivity, specificity, and positive and negative predictive values of each test. Results: In total, 8, 12 and 13 studies were included to assess the diagnostic accuracy of GeneXpert MTB/RIF(r), GenoType MTBDRplus (r) and GenoType MTBDRsl (r), respectively. The specificity of GeneXpert MTB/RIF(r) ranged between 91 and 100%, and its sensitivity between 33.3 and 100%. The sensitivity of GenoType(r) MTBDRplus (r) ranged between 88 and 100%. The sensitivity and specificity of GenoType MTBDRsl (r) to evaluate drug resistance ranged between 56 and 100% and 21 and 100%, respectively. Conclusion: The three diagnostic tests evaluated have shown an adequate diagnostic accuracy to detect MDR and XDR tuberculoses.

Low Levels of Extensively Drug-resistant Tuberculosis among Multidrug Resistant Tuberculosis Isolates and Their Relationship to Risk Factors: Surveillance in Tehran, Iran; 2006 to 2014

OBJECTIVES: Extensively drug-resistant tuberculosis (XDR-TB) is more expensive and difficult to treat than multidrug-resistant tuberculosis (MDR-TB), and outcomes for patients are much worse; therefore, it is important that clinicians understand the magnitude and distribution of XDR-TB. We conducted a retrospective study to compare the estimated incidence of and risk factors for M/XDR-TB with those of susceptible TB controls. METHODS: Sputum culture and drug susceptibility testing (DST) were performed in patients with known or suspected TB. Strains that were identified as MDR were subjected to DST for second-line drugs using the proportion method. RESULTS: Among 1,442 TB patients (mean age, 46.48 ± 21.24 years) who were culture-positive for Mycobacterium tuberculosis, 1,126 (78.1%) yielded isolates that were resistant to at least one first-line drug; there were 33 isolates (2.3%) of MDR-TB, of which three (0.2%) were classified as XDR-TB. Ofloxacin resistance was found in 10 (0.7%) isolates. Women were 15% more likely than men to yield M/XDR-TB isolates, but this difference was not significant. In a multivariate analysis comparing susceptible TB with X/MDR-TB, only one variable—the number of previous treatment regimens—was associated with MDR (odds ratio, 1.06; 95% confidence interval, 1.14–21.2). CONCLUSION: The burden of M/XDR-TB cases is not sizeable in Iran. Nonetheless, strategies must be implemented to identify and cure patients with pre-XDR-TB before they develop XDR-TB. Our results provide a greater understanding of the evolution and spread of M/XDR-TB in an environment where drug-resistant TB has a low incidence.

Padronização e implantação do teste de susceptibilidade aos fármacos de 2° linha para Mycobacterium tuberculosis: panorama da tuberculose extensivamente resistente no estado de São Paulo / Standardization and implantation of the susceptibility test for the drugs of 2nd line for Mycobacterium tuberculosis: panorama of the tuberculosis extensively resistant in the state of São Paulo

A resistência do Mycobacterium tuberculosis aos fármacos de 1º e 2ªlinha utilizados no tratamento da tuberculose (TB) é um problema de saúde pública. Em 2015, a Organização Mundial da Saúde estimou que 9,5% de todos os casos mundiais de TB multirresistente eram de TB extensivamente resistente (TBXDR). Este estudo teve como objetivo, padronizar o teste de susceptibilidade aos fármacos de 2ª linha pelo método BD BACTEC™MGIT™ 960 e descrever o panorama da TBXDR no estado de São Paulo nos anos de 2006 e 2011-2013. Dados clínicos, epidemiológicos e demográficos foram obtidos do sistema de notificação e acompanhamento de TB e os dados laboratoriais do Sistema de Informação e Gestão Hospitalar do Instituto Adolfo Lutz. Análises estatísticas foram realizadas com o auxílio do programa SPSS. O método BD BACTEC™ MGIT™ 960 demonstrou 100% de reprodutibilidade e foi validado por ensaio de proficiência. A prevalência de TBXDR em 2006, 2011, 2012 e 2013 foi de4,4%, 9,3%, 12% e 13,7% respectivamente. A ofloxacina foi o fármaco de 2ªlinha com maior porcentagem de resistência. Quanto aos fatores associados à TBXDR, a variável sexo, história anterior de TB, tipo de notificação e desfecho apresentaram diferenças estatisticamente significantes. A caracterização molecular demonstrou que 24 (63,1%) isolados de pacientes com TBXDR foram agrupados em nove grupos genéticos por RFLP-IS6110,e relações epidemiológicas foram observadas para onze pacientes (28,9%).Por meio da técnica de Spoligotyping foram observadas as famílias: Haarlem, T, LAM e X. O estudo possibilitou uma melhor compreensão do cenário da TBXDR no estado de São Paulo.

Drug Resistance Patterns of Multidrug- and Extensively Drug-Resistant Tuberculosis in Korea: Amplification of Resistance to Oral Second-line Drugs

We aimed to analyze the drug resistance patterns of multidrug-resistant and extensively drug-resistant tuberculosis (TB) and the difference of drug resistance among various settings for health care in Korea. The data of drug susceptibility testing in 2009 was analyzed in order to secure sufficient number of patients from various settings in Korea. Patients were categorized by types of institutions into four groups, which comprised new and previously treated patients from public health care centers (PHC), the private sector, and Double-barred Cross clinics (DBC). The resistance rates to first-line drugs were uniformly high in every group. While the resistance rates to second-line drugs were not as high as first-line drugs, there was a pattern that drug resistance rates were lowest for PHC and highest for DBC. The differences of the resistance rates were more prominent for oral second-line drugs. Our findings implied that drug resistance to oral second-line drugs was significantly amplified during multidrug-resistant-TB treatment in Korea. Therefore, an individualized approach is recommended for treating drug-resistant-TB based on susceptibility testing results to prevent acquisition or amplification of drug resistance.

Análisis genómico comparativo de cepas peruanas de Mycobacterium tuberculosis / Comparative genomic analysis of peruvian strains of Mycobacterium tuberculosis

RESUMEN Objetivos. Analizar comparativamente tres secuencias genómicas de Mycobacterium tuberculosis(MTB): INS-SEN,cepa sensible; INS-MDR, cepa multidrogorresistente e INS-XDR, cepa extensamente resistente, procedentes de la Ciudad de Lima, Perú. Materiales y métodos. Se identificaron los polimorfismos de un solo nucleótido (SNPs) específicos en las cepas INS-SEN, INS-MDR y INS-XDR mediante el criterio de inclusión/exclusión. Se compararon los tres genomas de MTB y se construyó una filogenia molecular con 27 cepas de MTB de otros estudios, disponibles de la base de datos Genbank. Los SNPs específicos en cada genoma fueron organizados en clústers de grupos ortólogos (COGs). Resultados. El análisis de genomas permitió identificar un conjunto de SNPs asociados a determinantes de virulencia (familia de proteínas mce, policetidos, phiRv1, transposasas, metiltransferasas y relacionados a síntesis de vitaminas) principalmente. Se observa una estrecha relación entre la cepa INS-MDR y INS-XDR, con solo un 6,1% de SNPs diferentes, sin embargo, la cepa INS-SEN presenta un 50,2 y 50,3% de SNPs diferentes a las cepas MDR y XDR, respectivamente. La filogenia molecular agrupó a las cepas peruanas dentro del linaje LAM y cercanamente a las cepas F11 y KZN de Sudáfrica. Conclusiones . Se evidenció una alta similitud (99,9%) de la cepa INS-SEN con la cepa sudafricana F11, de gran alcance mundial, mientras los análisis de las cepas INS-MDR e INS-XDR demuestran una probable expansión de la familia KZN, cepa de Sudáfrica con alta virulencia y patogenicidad.

ABSTRACT Objectives. To comparatively analyze three genomic sequences of Mycobacterium tuberculosis(MTB), including sensitive (INS-SEN), multi-drug-resistant (INS-MDR), and extremely drug-resistant (INS-XDR) strains, collected in Lima, Peru. Materials and Methods. Specific single nucleotide polymorphisms (SNPs) were identified in the INS SEN, INS-MDR, and INS-XDR strains according to the inclusion/exclusion criteria. The three MTB genomes were compared and a molecular phylogeny was constructed with 27 MTB strains from other studies available from the Genbank database. Results. The specific SNPs in each genome were organized in clusters of orthologous groups (COGs). The genomic analysis allowed for the identification of a set of SNPs associated mainly with virulence determinants (family of mce proteins, polyketides, phiRv1, transposase, and methyltransferases, and other related to vitamin synthesis). A close correlation between the INS-MDR and INS-XDR strains was observed, with only a 6.1% difference in SNPs; however, the INS-SEN strain had 50.2% and 50.3% different SNPs from the MDR and XDR strains, respectively. The molecular phylogeny grouped the Peruvian strains within the LAM lineage and closely to the F11 and KZN strains from South Africa. Conclusions. High similarity (99.9%) was noted between the INS-SEN strain and the F11 South African strain with broadglobal scope, while the analysis of the INS-MDR and INS-XDR strains showed a likely expansion of the KZN family, a South African strain with high virulence and pathogenicity.